Alaska Permanent Fund’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
– Sell
-23,149
Closed -$2.71M – 220
2025
Q1
$2.71M Hold
23,149
– – 0.04% 206
2024
Q4
$2.85M Hold
23,149
– – 0.04% 216
2024
Q3
$2.58M Hold
23,149
– – 0.04% 261
2024
Q2
$2.55M Buy
23,149
+2,609
+13% +$287K 0.04% 265
2024
Q1
$2.47M Buy
20,540
+1,739
+9% +$213K 0.04% 258
2023
Q4
$2.31M Buy
18,801
+481
+3% +$60K 0.04% 277
2023
Q3
$2.37M Sell
18,320
-62
-0.3% -$8.26K 0.04% 208
2023
Q2
$2.28M Buy
+18,382
New +$2.47M 0.04% 278
2022
Q4
$2.66M Hold
16,700
– – 0.04% 143
2022
Q3
$2.23M Hold
16,700
– – 0.04% 158
2022
Q2
$2.6M Buy
16,700
+2,100
+14% +$323K 0.04% 106
2022
Q1
$2.27M Hold
14,600
– – 0.04% 150
2021
Q4
$2.03M Hold
14,600
– – 0.04% 197
2021
Q3
$1.9M Hold
14,600
– – 0.04% 215
2021
Q2
$2.59M Sell
14,600
-1,300
-8% -$225K 0.05% 62
2021
Q1
$2.61M Hold
15,900
– – 0.05% 188
2020
Q4
$2.62M Hold
15,900
– – 0.05% 160
2020
Q3
$2.27M Buy
15,900
+8,510
+115% +$1.06M 0.04% 72
2020
Q2
$815K Hold
7,390
– – 0.01% 100
2020
Q1
$737K Buy
+7,390
New +$955K 0.01% 68

Other funds holding JAZZ

Alaska Permanent Fund's JAZZ Position: Q2 2025 in Review

Alaska Permanent Fund sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2025, closing a stake of 23,149 shares — an estimated $2.71M sold.

Alaska Permanent Fund first reported a position in JAZZ in Q1 2020 and held it in 20 quarters. The position peaked at $2.85M in Q4 2024. 502 funds tracked by Wall St. Rank hold JAZZ as of Q2 2025.

  • Alaska Permanent Fund reported no remaining Jazz Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Alaska Permanent Fund sold 23,149 Jazz Pharmaceuticals shares in Q2 2025, an estimated $2.71M.
  • Alaska Permanent Fund first reported a position in Jazz Pharmaceuticals in Q1 2020 and held it in 20 quarters.
  • Alaska Permanent Fund's Jazz Pharmaceuticals position peaked at $2.85M in Q4 2024.
  • 502 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2025.

Based on Alaska Permanent Fund's 13F filing for Q2 2025, filed 14 Aug 2025.